Interferon-Ribavirin in Association with Stavudine Has No Impact on Plasma Human Immunodeficiency Virus (HIV) Type 1 Level in Patients Coinfected with HIV and Hepatitis C Virus: A CORIST-ANRS HC1 Trial

Salmon-Céron, Dominique; Lassalle, Régis; Pruvost, Alain; Benech, Henri; Bouvier-Alias, Magali; Payan, Christopher; Goujard, Cécile; Bonnet, Eric; Zoulim, Fabien; Morlat, Philippe; Sogni, Philippe; Pérusat, Sophie; Tréluyer, Jean-Marc; Chêne, Geneviève
May 2003
Clinical Infectious Diseases;5/15/2003, Vol. 36 Issue 10, p1295
Academic Journal
A randomized, open-label trial was performed to study virological and intracellular interactions between stavudine and ribavirin in 30 patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Patients were randomized to receive either interferon and ribavirin or no treatment for HCV infection for 3 months. Intracellular peripheral blood mononuclear cells' stavudine-triphosphate (TP) concentrations were assessed. Plasma HIV RNA levels did not change significantly between baseline and month 3. There was a nonstatistically significant trend for a lower median residual concentration of intracellular stavudine-TP in the treated group, compared with the control group. The same trend was also observed for peak concentrations. Coprescription of ribavirin and stavudine has no short-term impact on plasma HIV RNA level in HIV-HCV-coinfected patients treated with stavudine as a part of their antiretroviral treatment; this coprescription can be safely used, although an in vivo interaction between ribavirin and stavudine is possible.


Related Articles

  • Peginterferon Plus Ribavirin for Chronic Hepatitis C in Patients With Human Immunodeficiency Virus. Gluud, Lise Lotte; Marchesini, Emanuela; Iorio, Alfonso // American Journal of Gastroenterology;Sep2009, Vol. 104 Issue 9, p2335 

    OBJECTIVES:The aim of this study was to assess the effects of peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus (HIV).METHODS:Trials were identified through manual and electronic searches. Randomized trials comparing peginterferon plus ribavirin...

  • Treatment of acute hepatitis C in HIV infection. Vogel, Martin; Rockstroh, Jürgen K. // Journal of Antimicrobial Chemotherapy (JAC);Jan2010, Vol. 65 Issue 1, p4 

    Within Europe and recently in the USA and Australia an ongoing epidemic of acute hepatitis C virus (HCV) infections among HIV-positive individuals, mainly men who have sex with men, has been observed. Other concomitant sexually transmitted diseases and sexual practices with a high risk of...

  • Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV. Medrano, Jose; Neukam, Karin; Rallón, Norma; Rivero, Antonio; Resino, Salvador; Naggie, Susanna; Caruz, Antonio; Calvino, Aida; Macías, Juan; Benito, Jose Miguel; Sánchez-Piedra, Carlos; Vispo, Eugenia; Barreiro, Pablo; McHutchison, John; Pineda, Juan Antonio; Soriano, Vincent // Clinical Infectious Diseases;11/15/2010, Vol. 51 Issue 10, p1209 

    Background. A single-nucleotide polymorphism (SNP) near the IL28B gene (rs12979860) strongly predicts sustained virological response to pegylated interferon plus ribavirin (pegIFN-RBV) treatment for chronic hepatitis C virus (HCV) infection. Given that therapy is poorly tolerated and rates of...

  • Review: Interferon-α plus ribavirin improves the virologic response in chronic hepatitis C. Reichen, Juerg // ACP Journal Club;Jul/Aug2002, Vol. 137 Issue 1, p17 

    Provides information on a study that examined whether interferon-α plus ribavirin more effective than interferon-α alone for improving hepatitis C virologic response and liver-related morbidity and mortality in patients with chronic hepatitis C. Data sources; Study selection; Main...

  • HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C. Romero-Gómez, Manuel; González-Escribano, María Francisca; Torres, Belén; Barroso, Natalia; Montes-Cano, Marco Antonio; Sánchez-Muñoz, Diego; Núñez-Roldan, Antonio; Aguilar-Reina, José // American Journal of Gastroenterology;Jul2003, Vol. 98 Issue 7, p1621 

    : ObjectiveThe aim of this study was to assess the influence of host genetic factors on response to combination therapy for chronic hepatitis C infection.: MethodsPatients with biopsy-proved chronic hepatitis C infection were treated with interferon alone (n = 143) or combined therapy of...

  • Immunological markers predicting outcome in patients with hepatitis C treated with interferon-α and ribavirin. Lee, Silvia; Macquillan, Gerry C; Keane, Niamh M; Flexman, James; Jeffrey, Gary P; French, Martyn Ah; Brochier, Jean; Price, Patricia // Immunology & Cell Biology;Aug2002, Vol. 80 Issue 4, p391 

    Summary Type 1 (T1) cytokine responses are required for the clearance of hepatitis C virus by cytotoxic T lymphocytes, but can promote liver damage. Interferon-α (IFNα) can be expected to promote T1 cytokine responses, so treatment outcome may depend on the T1/T2 cytokine environment and...

  • Interferon-α-2b Plus Ribavirin: A Review of its Use in the Management of Chronic Hepatitis C. Scott, L.J.; Perry, C.M. // Drugs;2002, Vol. 62 Issue 3, p507 

    Relatively few patients (≤20%) with chronic hepatitis C achieve a sustained virological response after interferon-α monotherapy. Hence, alternative treatment strategies such as the addition of the broad spectrum antiviral agent ribavirin to interferon-α-2b have been investigated....

  • Spontaneous Hepatic Decompensation in Patients Coinfected with HIV and Hepatitis C Virus during Interferon-Ribavirin Combination Treatment. Bani-Sadr, Firouzé; Carrat, Fabrice; Rosenthal, Eric; Piroth, Lionel; Morand, Patrice; Lunel-Fabiani, Françoise; Bonarek, Mojgan; de Verdiere, Nathalie Cohn; Pialoux, Gilles; Cacoub, Patrice; Pol, Stanislas; Perronne, Christian // Clinical Infectious Diseases;12/15/2005, Vol. 41 Issue 12, p1806 

    Spontaneous hepatic decompensation was observed in 7 of 383 patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) who were receiving treatment with interferon and ribavirin. Multivariate analysis identified the following risk factors: didanosine use (odds ratio...

  • Chronic Hepatitis C in HIV-Infected Patients: Those Who More Need Therapy are Those Who Respond Less. Soriano, Vincent; Nu�ez, Marina; Garcia-Samaniego, Javier; Labarga, Pablo; Simarro, Nuria; Martin-Carbonero, Luz; Ramos, Belen; Barreiro, Pablo // Infectious Disorders - Drug Targets;Mar2006, Vol. 6 Issue 1, p57 

    One third of HIV-infected individuals worldwide suffer from chronic hepatitis C virus (HCV) infection. Two main reasons justify considering HCV therapy as a priority in HIV-coinfected patients. First, these patients have more rapid liver disease progression, and second, they have a higher risk...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics